|
DE69942581D1
(de)
*
|
1998-05-25 |
2010-08-26 |
Nippon Shinyaku Co Ltd |
Verfahren zur herstellung einer nucleinsäure enthaltenden kompositzusammenstellung
|
|
CA2361201A1
(en)
*
|
1999-01-28 |
2000-08-03 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
|
EP1097993A3
(en)
*
|
1999-11-05 |
2004-01-07 |
National Institute of Advanced Industrial Science and Technology |
Functional ribozyme chimeric molecules capable of sliding
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7461046B2
(en)
*
|
2002-02-07 |
2008-12-02 |
The University Of Utah Research Foundation |
Method for creating and using a treatment protocol
|
|
US20040180438A1
(en)
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
|
CA2487274A1
(en)
|
2002-05-06 |
2003-11-13 |
Nucleonics Inc. |
Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
|
|
WO2003106636A2
(en)
*
|
2002-06-14 |
2003-12-24 |
Mirus Corporation |
Novel methods for the delivery of polynucleotides to cells
|
|
EP1540004A4
(en)
*
|
2002-07-31 |
2007-10-03 |
Nucleonics Inc |
DOUBLE-STRING RNA STRUCTURES AND CONSTRUCTS AND METHOD FOR THE PRODUCTION AND USE THEREOF
|
|
WO2004073631A2
(en)
*
|
2003-02-14 |
2004-09-02 |
Combinatorx, Incorporated |
Combination therapy for the treatment of neoplasms
|
|
EP2270162B1
(en)
|
2003-06-12 |
2018-10-03 |
Alnylam Pharmaceuticals Inc. |
Conserved hbv and hcv sequences useful for gene silencing
|
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
|
DE602005027479D1
(de)
|
2004-09-24 |
2011-05-26 |
Alnylam Pharmaceuticals Inc |
Targeting von zwischenprodukten zur gegenstrangreplikation von einzelstrangigen viren durch rnai
|
|
EP2316942B1
(en)
|
2004-12-22 |
2021-04-21 |
Alnylam Pharmaceuticals, Inc. |
Conserved hbv and hcv sequences useful for gene silencing
|
|
RU2423381C2
(ru)
|
2005-07-25 |
2011-07-10 |
Трабьон Фармасьютикалз, Инк. |
Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
|
|
NZ573646A
(en)
*
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
|
EP3255141B1
(en)
|
2006-07-13 |
2021-12-01 |
Wyeth LLC |
Production of antibodies with improved glycosylation pattern
|
|
DK2548438T3
(en)
|
2006-11-08 |
2015-10-19 |
Veritas Bio LLC |
IN VIVO SUBMITTING DOUBLE-STRENGTH RNA TO A CELL
|
|
JP2010532764A
(ja)
*
|
2007-07-06 |
2010-10-14 |
トゥルビオン・ファーマシューティカルズ・インコーポレーテッド |
Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
|
|
RU2531754C2
(ru)
|
2008-04-11 |
2014-10-27 |
ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US |
Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
|
|
WO2010129672A1
(en)
|
2009-05-05 |
2010-11-11 |
Miragen Therapeutics |
Lipophilic polynucleotide conjugates
|
|
SG176716A1
(en)
|
2009-06-08 |
2012-01-30 |
Miragen Therapeutics |
CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
|
|
AU2011234492B2
(en)
*
|
2010-04-01 |
2014-02-27 |
Palette Life Sciences AB |
Thermogelling anaesthetic compositions
|
|
WO2012061810A1
(en)
|
2010-11-05 |
2012-05-10 |
Miragen Therapeutics |
Base modified oligonucleotides
|
|
KR20140004646A
(ko)
|
2010-12-15 |
2014-01-13 |
미라젠 세러퓨틱스 |
잠금 뉴클레오티드를 포함하는 마이크로rna 억제제
|
|
CA2832899A1
(en)
|
2011-04-12 |
2012-10-18 |
Beth Israel Deaconess Medical Center, Inc. |
Micro-rna inhibitors and their uses in disease
|
|
EP2755663A4
(en)
|
2011-09-13 |
2015-10-07 |
Ottawa Hospital Res Inst |
MicroRNA Inhibitors
|
|
CN107236735B
(zh)
|
2012-06-21 |
2019-11-08 |
米拉根医疗股份有限公司 |
包含锁核酸基序的基于寡核苷酸的抑制剂
|
|
DK2970968T3
(en)
|
2013-03-15 |
2018-03-05 |
Miragen Therapeutics Inc |
CONNECTED BICYCLIC Nucleosides
|
|
CA2930693A1
(en)
|
2013-11-15 |
2015-05-21 |
The Board Of Trustees Of The Leland Stanford Junior Unversity |
Methods of treating heart failure with agonists of hypocretin receptor 2
|
|
US10772974B2
(en)
|
2013-11-18 |
2020-09-15 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for cardiac regeneration
|
|
CA2957618A1
(en)
|
2014-08-04 |
2016-02-11 |
MiRagen Therapeutics, Inc. |
Inhibitors of myh7b and uses thereof
|
|
US9376681B2
(en)
|
2014-09-08 |
2016-06-28 |
MiRagen Therapeutics, Inc. |
miR-29 mimics and uses thereof
|
|
EP3247716A4
(en)
|
2015-01-20 |
2018-10-17 |
Miragen Therapeutics, Inc. |
Mir-92 inhibitors and uses thereof
|
|
KR20190118688A
(ko)
|
2015-06-05 |
2019-10-18 |
미라젠 세러퓨틱스 인코포레이티드 |
피부 t 세포 림프종(ctcl) 치료용 mir-155 억제제
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
EP3377073A4
(en)
|
2015-11-16 |
2019-06-26 |
Ohio State Innovation Foundation |
METHOD AND COMPOSITIONS FOR TREATING DISORDERS AND DISEASES WITH THE SURVIVAL MOTOR NEURON (SMN) PROTEIN
|
|
WO2017222911A1
(en)
|
2016-06-20 |
2017-12-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Circular rnas and their use in immunomodulation
|
|
UY37376A
(es)
|
2016-08-26 |
2018-03-23 |
Amgen Inc |
Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
|
|
ES2659845B1
(es)
|
2016-09-19 |
2019-01-04 |
Univ Valencia |
Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello
|
|
UY38003A
(es)
|
2017-12-12 |
2019-06-28 |
Amgen Inc |
Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas
|
|
KR20200131287A
(ko)
|
2018-03-14 |
2020-11-23 |
베스 이스라엘 데코니스 메디칼 센터 |
마이크로-rna 22의 억제제
|
|
WO2020123410A1
(en)
|
2018-12-10 |
2020-06-18 |
Amgen Inc. |
CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
|
|
CR20210371A
(es)
|
2018-12-10 |
2021-08-27 |
Amgen Inc |
Constructos de arni para inhibir la expresión de pnpla3
|
|
CA3141902A1
(en)
|
2019-05-30 |
2020-12-03 |
Amgen Inc. |
Rnai constructs for inhibiting scap expression and methods of use thereof
|
|
US20220340911A1
(en)
|
2019-08-13 |
2022-10-27 |
Amgen Inc. |
Rnai constructs for inhibiting slc30a8 expression and methods of use thereof
|
|
MX2022007005A
(es)
|
2019-12-09 |
2022-08-25 |
Amgen Inc |
Construcciones de iarn y metodos para inhibir la expresion de lpa.
|
|
WO2021234607A1
(en)
|
2020-05-20 |
2021-11-25 |
St. Jude Children's Research Hospital |
Detection of alzheimer's disease using specific biomarkers
|
|
KR20240004092A
(ko)
|
2020-06-01 |
2024-01-11 |
암젠 인크 |
Hsd17b13 발현을 억제하기 위한 rnai 작제물 및 이의 사용 방법
|
|
EP3929295A1
(en)
|
2020-06-26 |
2021-12-29 |
Universitat Pompeu Fabra |
Artificial rnas for modulating rna fragments
|
|
KR20230046319A
(ko)
|
2020-08-13 |
2023-04-05 |
암젠 인크 |
MARC1 발현을 억제하기 위한 RNAi 작제물 및 방법
|
|
AU2021373780A1
(en)
|
2020-11-05 |
2023-06-08 |
Amgen Inc. |
METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
|
|
WO2023278295A1
(en)
|
2021-06-29 |
2023-01-05 |
The Broad Institute, Inc. |
Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
|
|
WO2023059629A1
(en)
|
2021-10-05 |
2023-04-13 |
Amgen Inc. |
Compositions and methods for enhancing gene silencing activity of oligonucleotide compounds
|
|
WO2023069754A2
(en)
|
2021-10-22 |
2023-04-27 |
Amgen Inc. |
Rnai constructs for inhibiting gpam expression and methods of use thereof
|
|
US20240084301A1
(en)
|
2022-07-25 |
2024-03-14 |
Amgen Inc. |
Rnai constructs and methods for inhibiting fam13a expression
|
|
EP4353823A1
(en)
|
2022-10-12 |
2024-04-17 |
Resalis Therapeutics S.r.l. |
Inhibitors of micro-rna 22
|
|
JP2025541245A
(ja)
|
2022-12-16 |
2025-12-18 |
アムジェン インコーポレイテッド |
Ｔｔｒ発現を阻害するためのｒｎａｉコンストラクト及びその使用方法
|
|
WO2025260042A1
(en)
|
2024-06-14 |
2025-12-18 |
Amgen Inc. |
Rnai constructs and methods for inhibiting cnr1 expression
|
|
WO2026006275A2
(en)
|
2024-06-26 |
2026-01-02 |
Amgen Inc. |
Rnai constructs and methods for inhibiting expression of inhbe
|